Iovance Biotherapeutics, Inc. IOVA Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s net change in cash?
- Iovance Biotherapeutics, Inc. (IOVA) reported net change in cash of $33.44M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s net change in cash changed year-over-year?
- Iovance Biotherapeutics, Inc.'s net change in cash decreased by 40.3% year-over-year, from $56M to $33.44M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s net change in cash?
- Over 2 years (2022 to 2024), Iovance Biotherapeutics, Inc.'s net change in cash has grown at a -37.9% compound annual growth rate (CAGR), from $153.85M to -$59.27M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.